Affinity Investment Advisors LLC Boosts Position in Amgen Inc. (AMGN)

Affinity Investment Advisors LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 86,970 shares of the medical research company’s stock after buying an additional 884 shares during the period. Affinity Investment Advisors LLC’s holdings in Amgen were worth $14,269,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of AMGN. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. First Command Financial Services Inc. raised its stake in shares of Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock worth $254,000 after buying an additional 17 shares during the period. Cribstone Capital Management LLC raised its stake in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after buying an additional 25 shares during the period. Cable Hill Partners LLC raised its stake in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock worth $161,000 after buying an additional 26 shares during the period. Finally, Howe & Rusling Inc. raised its stake in shares of Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock worth $485,000 after buying an additional 31 shares during the period. Institutional investors own 79.12% of the company’s stock.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.22% on Monday, reaching $167.65. 292,002 shares of the company’s stock traded hands. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The stock has a 50-day moving average price of $174.04 and a 200-day moving average price of $168.05. The company has a market cap of $122.33 billion, a PE ratio of 15.27 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.75%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

TRADEMARK VIOLATION NOTICE: “Affinity Investment Advisors LLC Boosts Position in Amgen Inc. (AMGN)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/08/21/affinity-investment-advisors-llc-boosts-position-in-amgen-inc-amgn.html.

AMGN has been the topic of a number of recent analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $178.00 price target on shares of Amgen in a report on Tuesday, April 25th. Cowen and Company reissued a “buy” rating and issued a $209.00 price target on shares of Amgen in a report on Thursday, April 27th. Robert W. Baird reissued a “neutral” rating and issued a $165.00 price target on shares of Amgen in a report on Friday, April 28th. Mizuho set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $186.64.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply